Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation
复制标题
DOI：
10.1016/j.lungcan.2012.05.092
复制
发表时间：
2012-09-01
期刊：
影响因子：
5.3
通讯作者：
Lee, J. S.
中科院分区：
文献类型：
--
作者：
Park, S. J.;Kim, H. T.;Lee, J. S.
携带活化表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）对EGFR酪氨酸激酶抑制剂（TKI）显示出良好和快速的反应。我们前瞻性评价了EGFR TKI治疗携带EGFR突变的NSCLC患者转移性脑肿瘤的疗效。这是一项开放标签、单机构、II期研究。诊断为携带EGFR突变和可测量的转移性脑肿瘤的NSCLC患者合格。他们接受厄洛替尼或吉非替尼，每天一次。在入组的28例患者中，23例患者（83%）显示部分缓解（PR），3例患者（11%）显示疾病稳定（SD），疾病控制率为93%。中位无进展生存期（PFS）和总生存期（OS）分别为6. 6个月（95% CI，3. 8 - 9. 3个月）和15. 9个月（95% CI，7. 2 - 24. 6个月）。根据使用的EGFR TKI，PFS和OS无差异。在停止治疗后，14例患者（50%）在其病程期间接受了转移性脑肿瘤的局部治疗，全脑放疗或放射外科治疗，无局部治疗间隔为12.6个月（95% CI，7.6-17.6个月）。EGFR TKI治疗可能是携带EGFR激活突变的NSCLC患者转移性脑肿瘤的治疗选择。(c)2012爱思唯尔爱尔兰有限公司保留所有权利。
Non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase inhibitors (TKIs). We prospectively evaluated the efficacy of EGFR TKI for metastatic brain tumors in NSCLC patients harboring EGFR mutation. This was an open-label, single-institution, phase II study. Patients diagnosed with NSCLC harboring EGFR mutation and measurable metastatic brain tumors were eligible. They received either erlotinib or gefitinib once a day. Out of total 28 patients enrolled, 23 patients (83%) showed a partial response (PR) and 3 patients (11%) did stable disease (SD), giving a disease control rate of 93%. Median progression free survival (PFS) and overall survival (OS) were 6.6 months (95% CI, 3.8-9.3 months) and 15.9 months (95% CI, 7.2-24.6 months), respectively. There was no difference in PFS and OS according to EGFR TKIs used. After discontinuation of the treatment, 14 patients (50%) received local therapy for metastatic brain tumors during their disease course, either whole brain radiotherapy or radiosurgery, giving a local therapy-free interval of 12.6 months (95% CI, 7.6-17.6 months). EGFR TKI therapy might be the treatment of choice for metastatic brain tumors in NSCLC patients harboring an activating EGFR mutation. (c) 2012 Elsevier Ireland Ltd. All rights reserved.